Research and Markets: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review 2013

Fri Apr 5, 2013 1:52pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130405:nBw055718a

DUBLIN--(Business Wire)--

Research and Markets

(http://www.researchandmarkets.com/research/r9h6ff/acute_myelocytic) has
announced the addition of the "Acute Myelocytic Leukemia (AML, Acute
Myeloblastic Leukemia) - Pipeline Review, H1 2013" report to their offering. 

Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic
Leukemia) - Pipeline Review, H1 2013', provides an overview of the indication's
therapeutic pipeline. This report provides information on the therapeutic
development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia),
complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic
development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review,
Half Year is built using data and information sourced from Global Markets
Direct's proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global Markets
Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia
(AML, Acute Myeloblastic Leukemia). 

- A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources. 

- Coverage of products based on various stages of development ranging from
discovery till registration stages. 

- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics. 

- Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
pipeline on the basis of route of administration and molecule type. 

- Key discontinued pipeline projects. 

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under
development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). 

- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage. 

- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline. 

- Devise corrective measures for pipeline projects by understanding Acute
Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus
of Indication therapeutics. 

- Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope. 

- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline. 

For more information visit
http://www.researchandmarkets.com/research/r9h6ff/acute_myelocytic

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.